# Bradley Murray

> Bradley Murray is the Boston-based CEO and co-founder of Delve Bio, where he is helping turn academic metagenomic sequencing into an operational clinical service. His route to the corner office ran through cancer-genome algorithms at the Broad Institute, CRISPR programs at Intellia Therapeutics, and early-stage life-sciences investing at Xontogeny. That mix of biology, software, finance, and execution now shapes Delve's attempt to make broad pathogen detection a practical part of diagnostic work.

- **Role:** CEO and Co-Founder at Delve Bio
- **Organizations:** Delve Bio, Xontogeny, Intellia Therapeutics, Broad Institute of MIT and Harvard, Vertex Pharmaceuticals, Georgetown University Office of Technology Commercialization Advisory Board
- **Education:** BS in Biology and Economics, Georgetown University, MBA in Finance and Entrepreneurship, Boston College Carroll School of Management
- **Known for:** Co-founded Delve Bio and serves as its CEO., Helped Delve Bio raise a $35 million Series A in 2023., Helped move Delve Detect from licensed academic technology to a commercially launched clinical service in 2024.

## Career timeline

- **Before 2015** — Worked as a computational associate at the Broad Institute, developing algorithms for cancer-genome sequencing analysis; also completed an internship at Vertex Pharmaceuticals.
- **2015-2020** — Held computational science roles at Intellia Therapeutics, progressing to management and helping build T-cell therapeutic platform capabilities for CRISPR/Cas9 programs.
- **2020** — Joined Xontogeny as a senior associate focused on seed and Series A life-sciences investments; he later remained an advisor.
- **2022** — Co-founded Delve Bio and became CEO.
- **2023** — Led Delve Bio's public launch with a $35 million Series A financing.
- **2024** — Delve Bio launched Delve Detect; Murray was a co-author on the seven-year clinical performance study published in Nature Medicine.
- **2025** — Appeared on the Diagnosing Dx podcast to discuss execution, evidence, reimbursement, and scaling diagnostics.
- **2026** — Represented Delve Bio in public discussion of metagenomic diagnostics, including a New Yorker laboratory visit and the Precision Medicine Tri-Conference.

## Achievements

- Co-founded Delve Bio and serves as its CEO.
- Helped Delve Bio raise a $35 million Series A in 2023.
- Helped move Delve Detect from licensed academic technology to a commercially launched clinical service in 2024.
- Co-authored a seven-year clinical performance study of cerebrospinal-fluid metagenomic sequencing published in Nature Medicine in 2024.
- At Intellia Therapeutics, contributed computational, genomic, gene-editing, and machine-learning expertise to in-vivo and ex-vivo CRISPR/Cas9 therapeutic programs.
- At the Broad Institute, developed cancer-genome analysis algorithms linked by Xontogeny to new drug targets, clinical trials, and highly cited publications.
- Serves on Georgetown University's Office of Technology Commercialization Advisory Board.

## Latest updates

- **2026-08** — Featured in a New Yorker report after walking the writer through Delve Bio's East Coast laboratory workflow.
- **2026-06** — Delve Bio reported additional case-based evidence on the use of Delve Detect for complex central nervous system infections.
- **2026-05** — Listed as a diagnostics-innovation speaker at the 33rd Precision Medicine Tri-Conference.
- **2025-11** — Highlighted Delve Bio's evidence presented at the Association for Molecular Pathology annual meeting.
- **2025-08** — Appeared on the Diagnosing Dx podcast to discuss execution, evidence, reimbursement, and scaling diagnostic businesses.

## Links

- Website: https://www.delve.bio
- LinkedIn: https://www.linkedin.com/in/bradley-murray-30646a47

---

Profile page: https://yespress.io/bradley-murray
Published by YesPress — https://yespress.io
Last updated: 2026-08-26